



Published in final edited form as:

J Addict Dis. 2016 ; 35(1): 22–35. doi:10.1080/10550887.2016.1100960.

Retention in Medication-Assisted Treatment for Opiate Dependence: A Systematic Review

Christine Timko^{1,2}, Nicole R Schultz³, Michael A Cucciare^{4,5,6}, Lisa Vittorio⁷, and Christina Garrison-Diehn^{1,2,8}

¹Center for Innovation to Implementation, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA

²Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA

³Department of Psychology, Auburn University, Auburn, AL

⁴Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Affairs Healthcare System, North Little Rock, AR

⁵VA South Central (VISN 16) Mental Illness Research, Education, and Clinical Center, Central Arkansas Veterans Healthcare System, North Little Rock, AR

⁶Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR

⁷Research Service, Veterans Affairs Boston Healthcare System, Brockton, MA

⁸Geriatric Research, Education, & Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA

Abstract

Retention in medication-assisted treatment (MAT) among opiate-dependent patients is associated with better outcomes. This systematic review (55 articles, 2010–2014) found wide variability in retention rates (i.e., 19%–94% at 3-month, 46%–92% at 4-month, 3%–88% at 6-month, and 37%–91% at 12-month follow-ups in randomized controlled trials), and identified medication and behavioral therapy factors associated with retention. As expected, patients who received naltrexone or buprenorphine had better retention rates than patients who received placebo or no medication. Consistent with prior research, methadone was associated with better retention than buprenorphine/naloxone. And, heroin-assisted treatment was associated with better retention than methadone among treatment-refractory patients. Only a single study examined retention in MAT for longer than one year, and studies of behavioral therapies may have lacked statistical power; thus, studies with longer-term follow-ups and larger samples are needed. Contingency Management showed promise to increase retention, but other behavioral therapies to increase retention, such as supervision of medication consumption, or additional counseling, education, or support, failed to find differences between intervention and control conditions. Promising behavioral therapies to increase retention have yet to be identified.

Keywords

opiate dependence; systematic review; treatment retention; behavioral therapies; medication-assisted treatment

Introduction

Opiate use and dependence are global problems.¹ The US has seen a significant increase in the illicit use of prescription opiates and stable levels of heroin use.^{2,3} In 2007, there were approximately 1.2 million heroin users in the US, and 5.2 million people reporting inappropriate use of prescription opioids.⁴ Among people who use heroin or prescription opiates, 50% and 11%, respectively, meet addiction criteria.⁵ Opiate dependence in particular is viewed as a chronic, brain-based disorder with a high potential for relapse.^{6,7}

The burden of opiate dependence is substantial, with high rates of morbidity and mortality, disease transmission, crime and law enforcement costs, family distress, lost productivity, and increased health care utilization.⁸ In the US, opiates are second only to alcohol as the primary reason for addiction treatment admission. From 1999 to 2009, annual treatment admissions for opiate misuse increased from approximately 280,000 to 421,000 individuals.⁹ A primary outcome in treating opiate dependence is retention in treatment because retention is associated with decreased drug use, improved social functioning and quality of life, and reduced mortality.^{8,10} Because of the benefits of retention for other outcomes, this systematic review examined factors associated with retention in medication-assisted treatment for opiate dependence.

Medication-Assisted Treatment

Medications approved by the FDA for the treatment of opiate dependence are methadone, buprenorphine, and naltrexone. The safety of methadone is well established.¹⁰ Methadone is used as a substitute for heroin or other opiates and, through mechanisms of tolerance and cross-tolerance, prevents opioid intoxication and withdrawal.⁸ Methadone is administered orally in liquid, tablet, or dispersible tablet formulation and is used for maintenance and for assisting in withdrawal.^{1,10} It is dispensed in specialized outpatient Methadone Maintenance clinics. Research has demonstrated methadone's efficacy in reducing heroin use, morbidity and mortality, and illegal activities.¹¹⁻¹⁴ Most patients require daily doses, and any "take-home" doses are strictly regulated to prevent diversion.¹⁵

Safety evaluations for buprenorphine are less developed than for methadone, but research suggests it is safe, with adverse effects equivalent to those of methadone and placebo.¹⁰ Buprenorphine, a partial opioid agonist, is administered sublingually in tablet or film formulations. It is also used in opiate detoxification and maintenance treatment.¹ It is available both as a monotherapy and in combination with naloxone to reduce the harm associated with buprenorphine injection. Indeed, naloxone was combined with buprenorphine to decrease the potential for diversion and misuse of buprenorphine. Because buprenorphine is a partial agonist, associated physical dependence and withdrawal are less severe than with full agonists.¹ Another advantage is its availability as a prescription

medication outside of the highly regulated methadone clinic system; it can be taken once every two days, which makes it more appealing to many patients.¹⁶ However, buprenorphine is relatively more expensive than methadone, making it more readily available to individuals with adequate resources.¹

Naltrexone's safety is also well demonstrated, but evidence of its efficacy has not been strongly established.^{8,10,17,18} Naltrexone is administered orally in tablet formulation or intramuscularly in an extended-release formulation.¹⁰ Extended-release naltrexone is delivered by injection once per month. Subdermal implants for naltrexone are not currently FDA approved, although they are available at a limited number of treatment centers. Naltrexone completely blocks the effects of opioids and produces no euphoric effects.¹

Present Study

The purpose of the present study is to identify factors associated with the outcome of retention in medication-assisted treatment (MAT) for opiate dependence; that is, treatment with methadone, buprenorphine, and naltrexone. We conducted a systematic review focused on comparisons of medications and behavioral therapies. Both sets of factors are modifiable and can be targeted for change to achieve better retention related to MAT. This review is intended to fill a critical gap in the literature in that identification of factors that promote higher rates of MAT retention will be useful to clinical providers and managers of addiction services seeking to achieve better outcomes among their opiate-dependent patients.

Method

To begin the systematic review, we entered the following search string in PubMed: (“opiate substitution treatment”[Mesh] OR “Opioid-Related Disorders/drug therapy”[Mesh] OR “Opioid-Related Disorders/rehabilitation”[Mesh]) AND (“naltrexone”[Mesh] OR “buprenorphine”[Mesh] OR “methadone”[Mesh]). The search (conducted on January 15, 2015) was limited to studies of humans reported in English language journal articles and published after December 31, 2009. This time frame was chosen to ensure that findings are relevant to current treatment programs, and also to constrain the studies to a manageable number for review. Excluded were case studies, abstracts, reviews, and commentaries. We also entered the same search string, publication date limits, and other constraints in CINAHL, using the option to exclude articles identified in MEDLINE (which is accessed within PubMed). From PubMed, a total of 289 unique citations were screened for inclusion. From CINAHL, only one additional citation was identified and screened, for a total of 290 unique citations.

Each citation (abstract) was reviewed by two authors; a full article review was conducted if one or both authors considered it to be indicated (the two authors agreed initially on the status of 285 of the 290 abstracts [98%]). Studies were eliminated at this stage of abstract review mainly because they focused on adults who were not opiate-dependent, on infants born to women maintained on opioid agonist medication, on short-term detoxification rather than medication-assisted treatment, or on biochemical effects of medications (e.g., hepatic safety). With this approach, 69 articles were retained for full text review because they possibly examined factors associated with retention in MAT for opiate dependence (Figure

1). Two authors conducted data extraction on each of the final 55 articles (elimination of 14 articles was also agreed upon by two authors' reviews). Data collected from each study included study design, conditions, total number of participants (and percent male), type of medication, measure of retention, and retention rate. All articles retained reported studies of individuals with opiate dependence. When studies provided retention rates at more than one follow-up point, we coded the rate for the longest follow-up.

Regarding study design, the US Preventive Services Task Force's quality rating criteria for individual studies rates randomized controlled trials (RCTs) the highest.¹⁹ Therefore, we separated RCTs from studies with other designs. In non-RCT designs, quasi-experimental studies are rated higher than cohort designs or case-control studies.¹⁹ More fine-grained criteria rate prospective cohort higher than retrospective cohort studies, and rate cohort studies higher than case-control studies.²⁰

Results

MAT Retention Rates

The RCTs listed in Table 1 found a wide range of retention in MAT at follow-ups of 1 month (72.0%; N=1 RCT), 3 months (19.0% to 94.1%; N=9 RCTs), 4 months (45.9% to 91.9%; N=4 RCTs), 6 months (3.0% to 88.0%; N=13 RCTs), and 12 months (37.0% to 90.7%; N=6 RCTs). Studies with a design other than RCT, listed on Table 2, also found a wide range of retention in MAT at follow-ups of 3 (68.0% to 87.0%, N=1 study), 6 (21.4% to 78.1%; N=6 studies), or 12 (26.0% to 85.0%, N=6 studies) months.

RCTs with a Medication Focus

Significant findings.—We focus first on RCTs that compared medication delivery conditions. (See Table 1, in which rates in the last column are significantly different within a given study unless otherwise noted in the table. Also, summaries of studies in this narrative follow the same order of studies in the table.) Patients receiving a 4-week rather than a briefer buprenorphine taper prior to naltrexone had higher MAT retention rates (50.0%) at 3-month follow-up.²¹ Receipt of a naltrexone implant rather than placebo was associated with a higher 3-month retention rate (52.0% vs 28.0%).²² Receipt of naltrexone rather than placebo was also associated with higher 6-month retention rates (20%), and a longer duration of MAT, but the additional receipt of guanfacine (used for ADHD and hypertension) did not increase retention rates.^{23,24} Receipt of buprenorphine rather than placebo was associated with a higher 6-month retention rate (65.7% vs 30.9%).²⁵ When all patients received counseling, receipt of buprenorphine rather than placebo or naltrexone was again associated with a higher 6-month retention rate.²⁶ Among patients who were HIV+, those receiving buprenorphine within the HIV clinic rather than a referral to an opioid treatment program were more likely to be in MAT at 12 months.²⁷ Thus, as expected, receipt of naltrexone or buprenorphine was associated with better retention in MAT than placebo or no medication.

Three studies found that receipt of methadone rather than buprenorphine/naloxone was associated with higher retention in MAT at 4 months (73.9% vs. 45.9%) and at 6 months

(74.0% vs 46.0%; 57.6% overall).^{28–30} Methadone receipt, compared to buprenorphine receipt, was also associated with higher end-of-pregnancy MAT retention rates among women receiving comprehensive pre-natal care and contingency management.³¹ However, among patients receiving oral methadone but still injecting heroin, 6-month retention rates were higher when patients were given injectable heroin (88.0%) or methadone (81.5%) than retained on oral methadone (69.0%); similar findings held at 12-month follow-up in another treatment-refractory sample.^{32,33} Similarly, among treatment-refractory patients, heroin-assisted treatment was associated with a higher 12-month retention rate than was methadone.^{34,35}

Non-significant findings.—Contrary to the studies cited above that found an advantage for methadone relative to buprenorphine,^{28–31} one study found that patients had high 3-month retention rates (85.0%) whether they received methadone or buprenorphine/naloxone, perhaps because the latter group also received a dose taper and referral to treatment, i.e., weekly individual drug counseling and group therapy.³⁶ Six-month MAT retention rates were also comparable (48%) for patients with chronic non-malignant pain who received either methadone or buprenorphine/naloxone.³⁷ High 12-month retention rates (88%) were found among treatment-refractory patients treated with either diacetylmorphine (the active ingredient of heroin) or hydromorphone (a semisynthetic opioid analgesic).³⁸ In another study, patients' 1-month retention in MAT did not differ according to whether they received direct or indirect induction of buprenorphine/naloxone.³⁹

Several studies failed to find significant effects on MAT retention for medications provided in addition to a primary opiate medication. In one, 3-month retention among patients receiving oral naltrexone did not differ according to whether they received varying doses of Memantine (a dementia drug) or a placebo (retention rates of 19%).⁴⁰ And, 3-month retention among patients receiving buprenorphine did not differ according to whether they received escitalopram or placebo for depression.⁴¹ Finally, among cocaine-dependent patients maintained on methadone for dual opioid dependence, those receiving disulfiram instead of placebo did not have a significantly different likelihood of MAT retention at a 4-month follow-up.⁴²

RCTs with a Behavioral Therapy Focus

Significant findings.—Among non-treatment-seeking hospitalized patients, a comparison of detoxification to facilitated linkage to buprenorphine treatment found higher rates of MAT retention among patients in the facilitated linkage condition; nevertheless, only 16.7% of linked patients were retained at 6 months.⁴³ Compared to methadone-only patients, patients receiving methadone with contingency management were more likely to be retained at 3 months (67.5% vs 81.7%; 67.0% vs 81.0%).^{44,45} Similarly, compared to naltrexone-only patients, patients receiving naltrexone and contingency management were more likely to be retained at 6 months (16.0% vs 54.0%).⁴⁶

Non-significant findings.—Several studies have examined MAT retention rates associated with different behavioral therapies among patients receiving methadone. Daily supervision of consumption was associated with a lower, but not significantly lower, 12-

month retention rate (72.7%) compared to twice-weekly (85.7%) or no (94.1%) supervision.⁴⁷ Adding counseling to receipt of daily methadone did not increase 6-month MAT retention rates, which were 76% or higher.⁴⁸ The provision of pharmacist-delivered motivational interviewing did not improve 6-month retention rates compared to usual care (rates of 81%).⁴⁹ Patients whose methadone was accompanied by web-based education but reduced (fewer sessions of) counseling had a comparable rate of MAT retention as patients receiving methadone plus more counseling (and no education); results suggest that less counselor staffing does not interfere with retention, but the overall retention rate at 12 months was only 38.7%.⁵⁰ Varying counseling provision by whether it was routine or emergency only, in the context of different counselor caseloads and amounts of patient supervision, was not significantly associated with 4-month (89% to 92%) or 12-month (37% to 61%) retention rates.^{51,52}

Another set of studies examined MAT retention rates associated with different behavioral therapies among patients receiving buprenorphine. The provision of cognitive behavioral treatment, contingency management, or both, did not significantly improve 4-month retention rates compared to no additional treatment (rates = 65%).⁵³ Similarly, the provision of intensive rather than standard outpatient counseling did not improve 6-month retention rates (= 57%).⁵⁴ Furthermore, the provision of telephone support did not benefit 12-month retention rates (55.0%) above usual care (55.0%), although patients with at least three completed telephone support calls had higher retention rates than patients in usual care.⁵⁵

The lack of significant findings related to behavioral therapies and MAT retention holds among samples of more complex opioid-dependent patients. Among patients diagnosed with HIV receiving buprenorphine/naloxone, patients provided with physician management only had an 80% 3-month retention rate compared to 59.0% with enhanced medical management (drug and medication adherence counseling) added on to physician management; this difference was not significant.⁵⁶ Among partners of opioid-dependent pregnant women, participation in a support group, or receiving more comprehensive therapy, education, and case management, was not associated with number of days in MAT with methadone.⁵⁷ Among individuals who were under judicial supervision, adding psychosocial counseling to naltrexone treatment was not associated with MAT retention rates at 6-month follow-up.⁵⁸

Studies with non-RCT Designs with a Medication Focus

Significant findings.—Studies with a cohort design found methadone compared to buprenorphine was associated with better retention rates at 6 and 12 months, and compared to Jitai tablets (a traditional Chinese medicine used to treat neuropsychiatric disorders) at 12 months.^{59–63} Higher doses of buprenorphine, especially early in treatment, were associated with better retention in MAT at a 6-month follow-up.⁶⁴

Non-significant findings.—In contrast to studies finding an advantage for methadone, a large study of public outpatient programs in Italy found high rates of MAT retention at 12 months for both methadone (93%) and buprenorphine/naloxone (89%).^{59,61,62,65}

Studies with non-RCT Designs with a Behavioral Therapy Focus

Significant findings.—Among patients receiving buprenorphine/naloxone, a psychosocial program with group cognitive behavioral therapy yielded a higher MAT retention rate at 6 months (55%) than did brief counseling in primary care (33%) or individual counseling in opioid treatment (21%).⁶⁶ Patients on methadone maintenance had a higher 12-month retention rate in a contingency management take-home condition (74%) than in a daily supervision (58%) or non-contingent take-home condition (50%).⁶⁷ In a retrospective cohort study of patients receiving buprenorphine, MAT retention at 12-month follow-up was associated with the receipt of substance abuse counseling and psychiatric medication.⁶⁸

Non-significant findings.—A study of primary care patients receiving buprenorphine/naloxone found physician management with weekly dispensing to be marginally significantly associated with better retention (87% at 3 months) than physician management with dispensing 3 times per week plus cognitive behavioral therapy (68%).⁶⁹ Pregnant women who received vouchers for both MAT (methadone or buprenorphine) attendance and providing drug-free biological samples had a comparable retention rate at 1-month post-delivery to that of pregnant women who received vouchers for MAT attendance only.⁷⁰

Discussion

This systematic review, summarizing 55 articles published during the past five years (from 2010 through 2014), found wide variability in the rates at which opiate-dependent patients are retained in medication-assisted treatment. As expected, retention rates are likely to decrease as the duration of follow-up lengthens.^{51,52} Retention in treatment represents the accomplishment of system and program goals that are important for patients' attaining and sustaining substance-free and productive lives.^{71,72} This review identified medication factors and behavioral therapies associated with MAT retention to help clinical providers and managers of addiction services implement procedures linked to patients' achieving better outcomes.

Notably, only a single study examined retention for longer than one year, even though the National Institute on Drug Abuse (NIDA) recommends a minimum of one year in methadone maintenance treatment for best outcomes.⁷³ Indeed, despite extensive and prolonged use of methadone to treat heroin addiction since the mid-1960s, little is known about its effects over the long-term. The FDA issued in 2006 a physician safety alert regarding increased cardiac arrhythmias and deaths among methadone patients.⁷⁴ More recent Norwegian animal studies suggest that methadone may negatively affect cognitive functioning, such as learning and memory.⁷⁵ However, long-term studies of the effectiveness and consequences of MAT for opiate-dependence have yet to be conducted.

Medications and Retention

With regard to medications, this review found, as expected, that patients in RCTs who received naltrexone or buprenorphine had better 3-, 6-, or 12-month retention rates than patients who received placebo or no medication. RCTs and cohort studies also found that

patients who received methadone rather than buprenorphine/naloxone were more likely to be retained in MAT at 4- and 6-month follow-ups and at the end of pregnancy. As reviewed by Whelan and Remski (2012), there is significant evidence that better MAT outcomes for opioid dependence are associated with high activity at the μ receptor, for example, “the narcotic blockade” achieved with high doses of methadone; therefore, buprenorphine’s weaker μ activity may account for its poorer performance compared to methadone in clinical trials.⁷⁶ In addition, buprenorphine retains fewer people when doses are delivered flexibly or at low fixed doses, compared to fixed medium or high doses; however, fixed doses are rarely used in clinical practice.¹⁶ This is consistent with the finding cited here that higher doses of buprenorphine, especially early in treatment, were associated with better retention.⁶⁴

The studies in this review finding benefits to retention of heroin-assisted treatment relative to methadone among treatment-refractory patients agree with earlier evidence in support of treatment with fully supervised, self-administered injectable heroin, when compared with oral methadone, for individuals with long-term refractory heroin dependence.^{77–81} However, heroin prescription is a controversial approach to treatment because of the question of whether giving users the drug they are addicted to constitutes treatment at all. Nevertheless, in the short term, heroin prescription may be considered as an effective way to retain users in treatment who have a history of failing in other treatment settings, with consequent benefits in terms of reduced drug use, HIV-risk behavior, and crime, and better social reintegration.
82–84

Behavioral Therapies and Retention

In the RCTs reviewed, only the behavioral therapy of Contingency Management (CM) showed promise as an intervention to increase retention in MAT for opiate dependence. Similarly, Gerra et al.’s quasi-experimental study (2011) found a higher retention rate in a CM condition.⁶⁷ In one of the RCTs, in China, participants in the CM condition drew for prizes on an escalating scale for having ingested methadone on each of the previous three days or having submitted a drug-free urine specimen; prizes ranged from very small to small monetary incentives (1 Yuan or 15 cents US, to 20 Yuan or \$2.94 US).⁴⁵ In another RCT conducted in China, in the CM intervention, participants drew for prizes for seven consecutive days of taking methadone, on an escalating scale; prizes were vouchers that could be redeemed only to pay for treatment.⁴⁴ In the US, Dunn et al. (2012) found support for employment-based reinforcement of naltrexone adherence in terms of retention in MAT; in the CM condition, participants were required to ingest oral naltrexone under staff observation to gain access to a workplace where they could work and earn monetary vouchers.⁴⁶

The efficacy of CM in terms of better retention and other treatment outcomes has also been established in studies of individuals dependent on stimulants or nicotine, with the benefits most apparent early in treatment.^{85–88} Indeed, CM has relatively strong empirical support in the treatment of addictions, but even so, CM has had weak and uneven adoption in clinical practice.⁸⁹ The main barriers to use of CM are cost and ideology, such as beliefs by clinicians that CM does not address the underlying causes of addiction, or undermines a

patient's internal motivation for abstinence. These barriers have been addressed through the development of lower-cost adaptations as well as clinician trainings to address ideological concerns and make CM more community friendly.⁸⁹

Other than Contingency Management, RCTs of behavioral therapies to increase retention failed to find differences between conditions. However, some of these studies may have been inadequately powered.^{47,56} Nevertheless, the lack of efficacy for behavioral therapies tested provides consistency with the body of studies that failed to find additional medications for psychological conditions, such as depression, to be efficacious in increasing MAT retention for opiate dependence.

Limitations

The major limitation of this study is that we relied on only two databases, PubMed and CINAHL, for the search of the literature, and did not review gray literature (e.g., technical reports, conference proceedings) or unpublished studies of retention in MAT, which may be more likely to show no effect for interventions intended to improve retention. However, PubMed, a service of the US National Library of Medicine, provides access to MEDLINE, the NLM database of indexed citations and abstracts to medical, nursing, dental, health care, and preclinical sciences journal articles, and includes additional life sciences journals not in MEDLINE. We also selected only English-language articles, although there may be publications relevant to this review that are not in English. We used study design to indicate the methodological rigor of the studies reviewed, but did not report attrition rates by condition, or effect sizes pertaining to the strength of interventions. Future systematic reviews are needed to address the additional limitation that this study focused on medication and behavioral therapy factors related to retention in MAT for opiate addiction, to the exclusion of other factors such as patient determinants, and other outcomes such as abstinence and psychosocial functioning.

Conclusion

This systematic review covering the past five years of research on MAT retention by opiate-dependent individuals suggests a continued advantage for methadone over buprenorphine, although the implementation of buprenorphine at higher doses may overcome this difference. In addition, offering MAT with contingency management may be associated with higher retention rates. The methodological quality of the body of research on retention is good given the large number of investigations using RCT designs. However, it is critical to address longer-term associations between medications and behavioral therapies and outcomes of MAT such as retention.^{90,91} Together, studies in this systematic review suggest that practices can be managed to increase the retention of opiate-dependent patients in medication-assisted treatments and ultimately improve their quality of life.

Acknowledgements

This research was supported by a Senior Research Career Scientist Award (RCS 00-001) to Dr. Timko by the Department of Veterans Affairs (VA) Health Services Research and Development (HSR&D) Service, and an Advanced Fellowship to Dr. Garrison-Diehn by the VA Office of Academic Affairs. The views expressed are the

authors' and do not necessarily reflect those of the VA. No conflicts of interest are reported by any of the authors listed on this manuscript.

References

1. Pecoraro A, Ma M, Woody GE. The science and practice of medication-assisted treatments for opioid dependence. *Subst Use Misuse* 2012 Jun-Jul; 47(8–9):1026–1040. DOI: 10.3109/10826084.2012.663292 [PubMed: 22676570]
2. UNODC. World drug report 2011 New York: United Nations Publications; 2011 267 p. United Nations Publication Sales No. E.11.XI.10.
3. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: summary of national findings Rockville (MD): Office of Applied Studies; 2011 156 p. (DHHS Publication No. [SMA] 11–4658); (NSUDH Series H-41).
4. UNODC. World drug report 2007 New York: United Nations Publications; 2007 275 p. United Nations Publication Sales No. S.07.XI.5
5. Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health, 2010. ICPSR 32722. [updated 2014 Sep 05; cited 2015 Mar 26]. Available from <http://www.icpsr.umich.edu/icpsrweb/SAMHDA/studies/32722#cite>
6. Volkow ND, Li TK. Drug addiction: the Neurobiology of behavior gone awry. *Nat Rev Neurosci* 2004 12; 5(12):963–970. DOI: 10.1038/nrn1539 [PubMed: 15550951]
7. World Health Organization. Neuroscience of psychoactive substance use and dependence Geneva: World Health Organization; 2004 264 p.
8. Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. *Expert Opin Pharmacother* 2009 8; 10(11):1727–1740. DOI: 10.1517/14656560903037168 [PubMed: 19538000]
9. Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS). ICPSR 34876. [updated 2014 Sep 11; cited 2015 Mar 26]. Available from <http://www.icpsr.umich.edu/icpsrweb/SAMHDA/studies/34876>
10. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. *J Addict Dis*, 2012; 31(3):207–225. DOI: 10.1080/10550887.2012.694598 [PubMed: 22873183]
11. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database Syst Rev* 2009 7 8; Issue 3 Art. No.: CD002209 DOI:10.1002/14651858.CD002209.pub2
12. Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge. *Drug Alcohol Depend* 1998 11; 52(3):257–260. DOI: 10.1016/S0376-8716(98)00097-0 [PubMed: 9839152]
13. Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H, DePhilippis D, Stolley P, Abrutyn E. Human Immunodeficiency Virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. *J Acquir Immune Defic Syndr* 1993 9; 6(9):1049–1056. [PubMed: 8340896]
14. Ball JC, Ross A. The effectiveness of methadone maintenance treatment New York: Springer-Verlag 1991 283 p. DOI: 10.1007/978-1-4613-9089-3
15. Kleber HD. Methadone maintenance 4 decades later. *JAMA* 2008 11 19; 300(19):2303–2305. DOI: 10.1001/jama.2008.648 [PubMed: 19017918]
16. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst Rev* 2014 2 6; Issue 2 Art. No.: CD002207 DOI: 10.1002/14651858.CD002207.pub4
17. Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. *Addiction* 2006 4; 101(4):491–503. DOI: 10.1111/j.1360-0443.2006.01369.x [PubMed: 16548929]
18. Adi Y, Juarez-Garcia A, Wang D, Jowett S, Frew E, Day E, Bayliss S, Roberts T, Burls A. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. *Health Technol Assess* 2007; 11(6).

19. Harris R, Atkins D, Berg AO, Best D, Eden KB, Feightner JW. US Preventive Services Task Force procedure manual Rockville (MD): Agency for Healthcare Research and Quality; 2008 7 AHRQ Publication No. 08-05118-EF.
20. Petticrew M, Roberts H. Evidence, hierarchies, and typologies: horses for courses. *J Epidemiol Community Health* 2003 7; 57(7):527–529. DOI: 10.1136/jech.57.7.527 [PubMed: 12821702]
21. Sigmon SC, Dunn KE, Saulsgiver K, Patrick ME, Badger GJ, Heil SH, Brooklyn MD, Higgins ST. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. *JAMA Psychiatry* 2013 12; 70(12):1347–1354. DOI: 10.1001/jamapsychiatry.2013.2216 [PubMed: 24153411]
22. Tiihonen J, Krupitsky E, Verbitskaya E, Blokhina E, Mamontova O, Föhr J, Tuomola P, Kuoppasalmi K, Kiviniemi V, Zwartau E. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. *Am J Psychiatry* 2012 5; 169(5):531–536. DOI: 10.1176/appi.ajp.2011.11071121 [PubMed: 22764364]
23. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicenter randomized trial. *Lancet* 2011 4 30; 377(9776):1506–1513. DOI: 10.1016/S0140-6736(11)60358-9. [PubMed: 21529928]
24. Krupitsky E, Zwartau E, Blokhina E, Verbitskaya E, Tsoy M, Wahlgren V, Burakov A, Masalov D, Romanova TN, Palatkin V, Tyurina A, Yaroslavtseva T, Sinha R, Kosten TR. Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia. *Drug Alcohol Depend* 2013 10 1; 132(3):674–680. DOI: 10.1016/j.drugalcdep.2013.04.021 [PubMed: 23683793]
25. Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, Rosenthal RN, Beebe KL. Buprenorphine implants for treatment of opioid dependence. *JAMA* 2010 10 13; 304(14):1576–1583. DOI: 10.1001/jama.2010.1427 [PubMed: 20940383]
26. Ruger JP, Chawarski M, Mazlan M, Ng N, Schottenfeld R. Cost-effectiveness of buprenorphine and naltrexone for heroin dependence in Malaysia. *PLoS ONE* 2012; 7(12):e50673 DOI: 10.1371/journal.pone.0050673 [PubMed: 23226534]
27. Lucas GM, Chaudhry A, Hsu J, Woodson T, Lau B, Olsen Y, Keruly JC, Fiellin DA, Finkelstein R, Barditch-Crovo P, Cook K, Moore RD. Clinic-based treatment for opioid-dependent HIV-infected patients versus referral to an opioid treatment program. *Ann Intern Med* 2010 6 1; 152(11):704–711. DOI: 10.1059/0003-4819-152-11-201006010-00003 [PubMed: 20513828]
28. Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, Doraimani G, Tasissa G, Lokhnygina Y, Leimberger J, Bruce RD, McCarthy J, Wiest K, McLaughlin P, Bilangi R, Cohen A, Woody G, Jacobs P. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. *Drug Alcohol Depend* 2013 2; 128(1–2):71–76. DOI: 10.1016/j.drugalcdep.2012.08.002 [PubMed: 22921476]
29. Woody GE, Bruce D, Korthuis PT, Chhatre S, Poole S, Hillhouse M, Jacobs P, Sorensen J, Saxon AJ, Metzger D, Ling W. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. *J Acquir Immune Defic Syndr* 2014 7 1; 66(3):288–293. DOI: 10.1097/QAI.000000000000165 [PubMed: 24751432]
30. Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, Martin JA, Ang A, Baker R, Saxon AJ, Ling W. Buprenorphine/naltrexone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: Findings from starting treatment with agonist replacement therapies (START). *J Stud Alcohol Drugs* 2013 7; 74(4):605–613. [PubMed: 23739025]
31. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O’Grady KE, Selby P, Martin PR, Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. *N Engl J Med* 2010 12 9; 363(24):2320–2331. DOI: 1056/NEJMoa1005359 [PubMed: 21142534]
32. Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S, Williams H, Zador D, Evers R, Groshkova T, Charles V, Martin A, Forzisi L. Supervised injectable heroin or injectable methadone versus optimized oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. *Lancet* 2010 5 29; 375(9729):1885–1895. DOI: 10.1016/S0140-6736(10)60349-2 [PubMed: 20511018]

33. Oviedo-Joekes E, Guh D, Marsh DC, Brissette S, Nosyk B, Krausz M, Anis A, Christian WM, Spittal P, Schechter MT. Characteristics and response to treatment among Aboriginal people receiving heroin-assisted treatment. *Can J Public Health* 2010 May-Jun; 101(3):210–212. [PubMed: 20737811]
34. Nosyk B, Geller J, Guh D, Oviedo-Joekes E, Brissette S, Marsh DC, Schechter MT, Anis AH. The effect of motivation status on treatment outcome in the North American Opiate Medication Initiative (NAOMI) study. *Drug Alcohol Depend* 2010 9 1; 111(1–2):161–165. DOI: 10.1016/j.drugalcdep.2010.03.019 [PubMed: 20510549]
35. Eiroa-Orosa FJ, Verthein U, Kuhn S, Lindemann C, Karow A, Haasen C, Reimer J. Implication of gender differences in heroin-assisted treatment: Results from the German randomized controlled trial. *Am J Addict* 2010 Jul-Aug; 19(4):312–318. DOI: 10.1111/j.1521-0391.2010.00049.x [PubMed: 20653637]
36. Otiazhvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior—outcomes of a randomized trial. *Drug Alcohol Depend* 2013 12 1; 133(2):376–382. DOI: 10.1016/j.drugalcdep.2013.06.024 [PubMed: 23916321]
37. Neumann AM, Blondell RD, Jaanimagi U, Giambrone AK, Homish GG, Lozano JR, Kowalik U, Azadfar M. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and co-existent opioid addiction. *J Addict Dis* 2013 1; 32(1):68–78. DOI: 10.1080/10550887.2012.759872 [PubMed: 23480249]
38. Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Nosyk B, Krausz M, Anis A, Schechter MT. Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study. *J Subst Abuse Treat* 2010 6; 38(4):408–411. DOI: 10.1016/j.jsat.2010.03.003 [PubMed: 20359843]
39. Amass L, Pukeleviciene V, Subata E, Almeida AR, Pieri MC, D'Egidio P, Stankova Z, Costa A, Smyth BP, Sakoman S, Wei Y, Strang J. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. *Addiction* 2011 1; 107(1):142–151. DOI: 10.1111/j.1360-0443.2011.03577.x [PubMed: 21749526]
40. Bisaga A, Sullivan MA, Chang WY, Carpenter KM, Mariani JJ, Levin FR, Raby WN, Nunes EV. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. *Drug Alcohol Depend* 2011 12 1; 119(1–2):e23–e29. DOI: 10.1016/j.drugalcdep.2011.05.019 [PubMed: 21715107]
41. Stein MD, Herman DS, Kettavong M, Cioe PA, Friedmann PD, Tellioglu T, Anderson BJ. Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. *J Subst Abuse Treat* 2010 9; 39(2):157–166. DOI: 10.1016/j.jsat.2010.05.014 [PubMed: 20598836]
42. Oliveto A, Poling J, Mancino MJ, Feldman Z, Cubells JF, Pruzinsky R, Gonsai K, Cargile C, Sofuoglu M, Chopra MP, Gonzalez-Haddad G, Carroll KM, Kosten TR. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. *Drug Alcohol Depend* 2011 1 15; 113(2–3):184–191. DOI: 10.1016/j.drugalcdep.2010.07.022 [PubMed: 20828943]
43. Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesh LZ, Dossabhoy S, Stein M. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized controlled trial. *JAMA Intern Med* 2014 8; 174(8): 1369–1376. DOI: 10.1001/jamainternmed.2014.2556 [PubMed: 25090173]
44. Chen W, Hong Y, Zou X, McLaughlin MM, Xia Y, Ling L. Effectiveness of prize-based contingency management in a methadone maintenance program in China. *Drug Alcohol Depend* 2013 11; 133(1):270–274. DOI: 10.1016/j.drugalcdep.2013.05.028 [PubMed: 23831409]
45. Hser Y, Li J, Jiang H, Zhang R, Du J, Zhang C, Zhang B, Evans E, Wu F, Chang YJ, Peng C, Huang D, Stitzer ML, Roll J, Zhao M. Effects of a randomized contingency management intervention on opiate abstinence and retention in methadone maintenance treatment in China. *Addiction* 2011 10; 106(10):1801–1809. DOI: 10.1111/j.1360-0443.2011.03490.x [PubMed: 21793958]

46. Dunn K, Defulio A, Everly JJ, Donlin WD, Aklin WM, Nuzzo PA, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users. *Exp Clin Psychopharmacol* 2013; 21(1): 74–83. DOI: 10.1037/a0030743 [PubMed: 23205722]
47. Holland R, Matheson C, Anthony G, Roberts K, Priyadarshi S, Macrae A, Whitelaw E, Appavoo S, Bond C. A pilot randomised controlled trial of brief versus twice weekly versus standard supervised consumption in patients on opiate maintenance treatment. *Drug Alcohol Rev* 2012 6; 31(4):483–491. DOI: 10.1111/j.1465-3362.2011.00394.x [PubMed: 22150819]
48. Chawarski MC, Zhou W, Schottenfeld RS. Behavioral drug and HIV risk reduction counseling (BDRRC) in MMT programs in Wuhan, China: a pilot randomized clinical trial. *Drug Alcohol Depend* 2011 6 1; 115(3):237–239. DOI: 10.1016/j.drugalcdep.2010.09.024 [PubMed: 21159452]
49. Jaffray M, Matheson C, Bond CM, Lee AJ, McLernon DJ, Johnstone A, Skea L, Davidson B. Does training in motivational interviewing for community pharmacists improve outcomes from methadone patients? A cluster randomised controlled trial. *Int J Pharm Pract* 2014 2; 22(1):4–12. DOI: 10.1111/ijpp.12049 [PubMed: 23822820]
50. Marsch LA, Guarino H, Acosta M, Aponte-Melendez Y, Cleland C, Grabinski M, Brady R, Edwards J. Web-based behavioral treatment for substance use disorders as a partial replacement of standard methadone maintenance treatment. *J Subst Abuse Treat* 2014 1; 46(1):43–51. DOI: 10.1016/j.jsat.2013.08.012 [PubMed: 24060350]
51. Schwartz RP, Kelly SM, O’Grady KE, Gandhi D, Jaffe JH. Interim methadone treatment compared to standard methadone treatment: 4-month findings. *J Subst Abuse Treat* 2011 7; 41(1):21–29. DOI: 10.1016/j.jsat.2011.01.008 [PubMed: 21353445]
52. Schwartz RP, Kelly SM, O’Grady KE, Gandhi D, Jaffe JH. Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings. *Addiction* 2012 5; 107(5):943–952. DOI: 10.1111/j.1360-0443.2011.03700.x [PubMed: 22029398]
53. Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J. Comparison of behavioral treatment conditions in buprenorphine maintenance. *Addiction* 2013 10; 108(10):1788–1798. DOI: 10.1111/add.12266 [PubMed: 23734858]
54. Mitchell SG, Gryczynski J, Schwartz RP, O’Grady KE, Olsen YK, Jaffe JH. A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans. *Drug Alcohol Depend* 2013 3 1; 128(3), 222–229. DOI: 10.1016/j.drugalcdep.2012.08.027 [PubMed: 22999817]
55. Ruetsch C, Tkacz J, McPherson TL, Cacciola J. The effect of telephonic patient support on treatment for opioid dependence: outcomes at one year follow-up. *Addict Behav* 2012 5; 37(5): 686–689. DOI: 10.1016/j.addbeh.2012.01.013 [PubMed: 22348921]
56. Tetrault JM, Moore BA, Barry DT, O’Connor PG, Schottenfeld R, Fiellin DA, Fiellin LE. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. *J Subst Abuse Treat* 2012 12; 43(4):433–439. DOI: 10.1016/j.jsat.2012.07.011 [PubMed: 22938914]
57. Jones HE, Tuten M, O’Grady KE. Treating the partners of opioid-dependent pregnant patients: Feasibility and efficacy. *Am J Drug Alcohol Abuse* 2011; 37(3):170–178. DOI: 10.3109/00952990.2011.563336 [PubMed: 21410418]
58. Coviello DM, Cornish JW, Lynch KG, Alterman AI, O’Brien CP. A randomized trial of oral naltrexone for treating opioid-dependent offenders. *Am J Addict* 2010 Sep-Oct; 19(5):422–432. DOI: 10.1111/j.1521-0391.2010.00070.x [PubMed: 20716305]
59. Gryczynski J, Mitchell SG, Jaffe JH, Kelly SM, Myers CP, O’Grady KE, Olsen YK, Schwartz RP. Retention in methadone and buprenorphine treatment among African Americans. *J Subst Abuse Treat* 2013 9; 45(3):287–292. DOI: 10.1016/j.jsat.2013.02.008 [PubMed: 23566446]
60. Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. *J Subst Abuse Treat* 2010 12; 39(4):340–352. DOI: 10.1016/j.jsat.2010.07.009 [PubMed: 20817384]
61. Bounes V, Palmaro A, Lapeyre-Mestre M, Roussin A. Long-term consequences of acute pain for patients under methadone or buprenorphine maintenance treatment. *Pain Physician* 2013; 16:E739–E747. [PubMed: 24284855]

62. Serpelloni G, Gomma M, Genetti B, Zermiani M, Rimondo C, Mollica R, Gryczynski J, O'Grady KE, Schwartz RP. Italy's electronic health record system for opioid agonist treatment. *J Subst Abuse Treat* 2013 8; 45(2):190–195. DOI: 10.1016/j.jsat.2013.02.001 [PubMed: 23518287]
63. Hao SQ, Zhao M, Zhang RW, Zhang JC, Zhang J, Feng XS. The effectiveness comparison of Jitai tablets versus methadone in community-based drug treatment: a 1-year follow-up study. *Addict Beh* 2013 10; 38(10):2596–2600. DOI: 10.1016/j.addbeh.2013.05.013
64. Gryczynski J, Mitchell SG, Jaffe JH, O'Grady KE, Olsen YK, Schwartz RP. Leaving buprenorphine treatment: patients' reasons for cessation of care. *J Subst Abuse Treat* 2014 3; 46(3):356–361. DOI: 10.1016/j.jsat.2013.10.004 [PubMed: 24238714]
65. Curcio F, Franco T, Topa M, Baldassarre C. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey. *Eur Rev Med Pharmacol Sci* 2011 8; 15(8):871–874. [PubMed: 21845796]
66. Miotto K, Hillhouse M, Donovan R, Cunningham-Rathner J, Charuvastra C, Torrington M, Esagoff AE, Ling W. Comparison of buprenorphine treatment for opioid dependence in 3 settings. *J Addict Med* 2012 3; 6(1):68–76. DOI: 10.1097/ADM.0b013e318233d621 [PubMed: 22105061]
67. Gerra G, Saenz E, Busse A, Maremmi I, Ciccocioppo R, Zaimovic A, Gerra ML, Amore M, Manfredini M, Donnini C, Somaini L. Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance. *Prog Neuropsychopharmacol Biol Psychiatry* 2011 3 30; 35(2):483–489. DOI: 10.1016/j.pnpbp.2010.12.002 [PubMed: 21147192]
68. Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. *Drug Alcohol Dep* 2013; 1–2(1):127–135. DOI: 10.1016/j.drugalcdep.2012.12.008
69. Moore BA, Barry DT, Sullivan LE, O'Connor PG, Cutter CJ, Schottenfeld RS, Fiellin DA. Counseling and directly observed medication for primary care buprenorphine maintenance. *J Addict Med* 9 2012; 6(3):205–211. DOI: 10.1097/ADM.0b013e3182596492 [PubMed: 22614936]
70. Winklbaur-Hausknost B, Jagsch R, Graf-Rohrmeister K, Unger A, Baewert A, Langer M, Thau K, Fischer G. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. *Hum Psychopharmacol* 2013 1; 28(1):15–24. DOI: 10.1002/hup.2275 [PubMed: 23161599]
71. Knight DK, Logan SM, Simpson DD. Predictors of program completion for women in residential substance abuse treatment. *Am J Drug Alcohol Abuse* 2001; 27(1):1–18. [PubMed: 11373028]
72. Simpson DD, Joe GW, Dansereau DF, Chatham LR. Strategies for improving methadone treatment process and outcomes. *J Drug Issues* 1997 3; 27(2):239–260.
73. Blanken P, Hendricks VM, van Ree JM, van den Brink W. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. *Addiction* 2010 2; 105(2):300–308. DOI: 10.1111/j.1360-0443.2009.02754.x [PubMed: 19922517]
74. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney CP. QTc interval screening in methadone treatment. *Ann Int Med* 2009 3 17; 150(6):387–395. DOI: 10.7326/0003-4819-150-6-200903170-00103 [PubMed: 19153406]
75. Andersen JM, Klykken C, Morland J. Long-term methadone treatment reduces phosphorylation of CaMKII in rat brain. *J Pharm Pharmacol* 2012 6; 64(6):843–847. DOI: 10.1111/j.2042-7158.2012.01469.x [PubMed: 22571262]
76. Whelan PJ, Remski K. Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds. *J Neurosci Rural Pract* 2012 Jan-Apr; 3(1):45–50. DOI: 10.4103/0976-3147.91934 [PubMed: 22346191]
77. Perneger TV, Giner F, del Rio M, Mino A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. *BMJ* 1998 7 4; 317(7150):13–18. DOI: 10.1136/bmj.317.7150.13 [PubMed: 9651260]
78. van den Brink W, Hendriks VM, Blanken P, Koester MWJ, van Zwieten BJ, van Ree J. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. *BMJ* 2003; 327(724):310–315. DOI: 10.1136/bmj.327.7410.310 [PubMed: 12907482]

79. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence. *Br J Psychiatry* 2007; 191(1):55–62. DOI: 10.1192/bjp.106.026112 [PubMed: 17602126]
80. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence. *Br J Psychiatry* 2007 7; 191(1):55–62. DOI: 10.1192/bjp.106.026112 [PubMed: 17602126]
81. Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT. Diacetylmorphine versus methadone for the treatment of opioid addiction. *N Engl J Med* 2009; 361:777–786. DOI: 10.1056/NEJMoa0810635 [PubMed: 19692689]
82. Lloyd C, McKeganey N. *Drugs research: an overview of evidence and questions for policy* York: Joseph Rowntree Foundation; 2010 70p.
83. Metrebian N, Shanahan W, Wells B, Stimson GV. Feasibility of prescribing injectable heroin and methadone to opiate-dependent drug users: associated health gains and harm reductions. *Med J Aust* 1998 6 15; 168(12):596–600. [PubMed: 9673620]
84. March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. *J Subst Abuse Treat* 2006 9; 31(2):203–201. DOI: 10.1016/j.jsat.2006.04.007 [PubMed: 16919749]
85. Petitjean SA, Dursteler-MacFarland KM, Krokarc MC, Strasser J, Mueller SE, Degen B, Trombini MV, Vogel M, Walter M, Wiesbeck GA, Farronato NS. A randomized, controlled trial of combined cognitive-behavioral therapy plus prize-based contingency management for cocaine dependence. *Drug Alcohol Depend* 2014 12 1; 145:94–100. DOI: 10.1016/j.drugalcdep.2014.09.785 [PubMed: 25456571]
86. Rawson RA, McCann MJ, Flammino F, Shoptaw S, Miotto K, Reiber C, Ling W. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. *Addiction* 2006 2; 101(2):267–274. DOI: 10.1111/j.1360-0443.2006.01312.x [PubMed: 16445555]
87. Ledgerwood DM, Arfken CL, Petry NM, Alessi SM. Prize contingency management for smoking cessation: a randomized trial. *Drug Alcohol Depend* 2014 7 1; 140:208–212. DOI: 10.1016/j.drugalcdep.2014.03.032 [PubMed: 24793364]
88. Benishek LA, Dugosh KL, Kirby KC, Matejkowski J, Clements NT, Seymour BL, Fetting DS. Prize-based contingency management for the treatment of substance abusers: a meta-analysis. *Addiction* 2014 9; 109(9):1426–1436. DOI: 10.1111/add.12589 [PubMed: 24750232]
89. Carroll KM. Lost in translation? Moving contingency management and cognitive behavioral therapy into clinical practice. *Ann N Y Acad Sci* 2014; 1327:94–111. DOI: 10.1111/nyas.12501 [PubMed: 25204847]
90. Guttinger F, Gschwend P, Schulte B, Rehm J, Uchtenhagen A. Evaluating long-term effects of heroin-assisted treatment: the results of a 6-year follow-up. *Eur Addict Res* 2003 4; 9(2):73–79. DOI: 10.1159/000068811 [PubMed: 12644733]
91. Skinner ML, Haggerty KP, Fleming CB, Catalano RF, Gainey RR. Opiate-addicted parents in methadone treatment: long-term recovery, health and family relationships. *J Addict Dis* 2011 1; 30(1):17–26. DOI: 10.1080/10550887.2010.531670 [PubMed: 21218307]
92. Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, Friedmann PD, Nunes EV, Kinlock TW, Gordon MS, Schwartz RP, Nuwayser ED, O'Brien CP. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. *Subst Abus* 2012; 33(1):48–59. DOI: 10.1080/08897077.2011.609438 [PubMed: 22263713]
93. Fox AD, Sohler NL, Starrels JL, Ning Y, Giovanniello A, Cunningham CO. Pain is not associated with worse office-based buprenorphine treatment outcomes. *Subst Abus* 2012; 33(4):361–365. DOI: 10.1080/08897077.2011.638734 [PubMed: 22989279]
94. Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazeran LB, Chaudhry A, Cunningham CO, Gourevitch MN, Lum PJ, Sullivan LE, Schottenfeld RS, O'Connor PG. Drug treatment outcomes among HIV-infected opioid dependent patients receiving buprenorphine/naloxone. *J Acquir Immune Defic Syndr* 2011 3 1; 56(0–1):S33–S38. doi:10.1097/QAI.0b013e3182097537 [PubMed: 21317592]

95. Apelt SM, Scherbaum N, Golz J, Backmund M, Soyka M. Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care. *Pharmacopsychiatry* 2013 5; 46(3):94–107. DOI: 10.1055/s-0032-1330033 [PubMed: 23293011]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1. Article selection process for retention in medication-assisted treatment for opioid dependence. (Adapted from “Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement”)

Table 1.

Summary of published randomized controlled trials on medication and behavioral therapies potentially associated with retention in medication-assisted treatment for opiate dependence (N=38 studies)

<u>First author, year, country</u>	<u>Conditions</u>	<u>Sample N (% Male)</u>	<u>Medication</u>	<u>Retention outcome</u>	<u>Retention rate</u>
Sigmon ²¹ , 2013, USA	1 vs 2 vs 4 week taper; all received individual behavioral therapy (Community Reinforcement Approach)	Community, illicitly using prescription opioids; 70 (69.0)	BUP taper, then NTX	In MAT at 3 months	50.0% 4-week taper 21.0% 2-week taper 21.0% 1-week taper
Tiihonen ²² , 2012, Russia	NTX implant vs placebo (P) implant	Polydrug dependent; 100 (not provided)	NTX	In MAT at 2.5 months	52.0% NTX, 28.0% P
Krupitsky ²³ , 2011, Russia	NTX vs P; all received counseling	<30 days of detox + abstinence at least 7 days; 250 (88.0)	NTX	Number of days in MAT up to 180	Med=168 NTX, Med=96 P
Krupitsky ²⁴ , 2013, Russia	NTX+Guanfacine (G) vs NTX +GP vs NTXP+G vs NTXP+GP; all received counseling	Medically hospitalized; 301 (82.4)	NTX, G	In MAT at 6 months	26.7% NTX+G, 19.7% NTX+GP, 10.7% NTXP+G, 6.7% NTXP+G, NTX+G, NTX+GP, NTXP+G, NTXP+GP
Ling ²⁵ , 2010, USA	BUP vs P; all received counseling; 18 sites	In addiction treatment; 163 (68.7)	BUP	In MAT at 6 months	65.7% BUP 30.9% P
Ruger ²⁶ , 2012, Malaysia	P vs NTX vs BUP; all received counseling	Not provided; 126 (not provided)	BUP, NTX	In MAT at 6 months	15.4% P 20.9% NTX 40.9% BUP BUP>PNTX
Lucas ²⁷ , 2010, USA	HIV clinical-based BUP vs case management plus referral to opioid treatment program	HIV+, 93 (72.0)	BUP, MET	In MAT at 12 Months	Rates not provided; BUP>referral
Saxon ²⁸ , 2013, USA	BUP vs MET; 8 sites	MAT seekers; 1,269 (not provided)	BUP, MET	In MAT at 4 months	Significance not reported: 45.9% BUP 73.9% MET
Woody ²⁹ , 2014, USA	MET vs BUP/NLX; 9 sites	MAT patients; 1,269 (67.8)	MET, BUP/NLX	In MAT at 6 months	74.0% MET 46.0% BUP
Potter ³⁰ , 2013, USA	MET vs BUP/NLX; 9 sites	MAT patients; 1,269 (67.8)	MET, BUP/NLX	In MAT at 6 months	Rates not provided: 57.6% overall; BUP<MET
Jones ³¹ , 2010, USA, Austria, Canada	BUP vs MET; all received comprehensive care and contingency management; 7 sites	Pregnant women; 187 (0.0)	BUP, MET	In MAT at end of pregnancy	82.0% MET 67.0% BUP
Strang ³² , 2010, England	Supervised injectable (inj) MET vs supervised inj heroin vs optimized oral MET; all patients had a case worker	Receiving oral MET but still injecting heroin; 127 (73.0)	MET, heroin	In MAT at 6.5 months	Significance not reported: 81.5% inj MET 88.0% inj heroin 69.0% oral MET

<u>First author, year, country</u>	<u>Conditions</u>	<u>Sample N (% Male)</u>	<u>Medication</u>	<u>Retention outcome</u>	<u>Retention rate</u>
Oviedo- Joekes ³³ , 2010, Canada	Inj diacetylmorphine or inj hydromorphone vs oral MET	Treatment refractory; 192 (61.4)	Inj diacetyl- morphine, inj hydromorphone, MET	In MAT at 12 months	Aboriginals: 84.4% Inj 57.1% MET Non-Aboriginals 90.7% Inj 50.9% MET
Nosyk ³⁴ , 2010, Canada	Heroin-assisted treatment (HAT) vs MET	Treatment refractory; 251 (61.4)	HAT, MET	In MAT at 12 months	Rates not provided; Better in HAT vs MET
Eiroia- Orosa ³⁵ , 2010, Germany	HAT vs MET; all received psychosocial services	Treatment refractory or treatment dropouts; 1,015 (73.3)	Heroin, MET	In MAT at 12 months	Significance not reported: 67.2% HAT 40.0% MET
Otiashvili ³⁶ , 2013, Republic Of Georgia	MET vs BUP/NLX +dose taper+referral to treatment; all were offered individual and group counseling	Treatment settings; 80 (95.0)	MET, BUP/NLX	In MAT at 3 months	No difference: 85.0% overall
Neumann ³⁷ , 2013, USA	MET vs BUP/NLX	Chronic non-malignant pain patients; 54 (53.7)	MET, BUP/NLX	In MAT at 6 months	48.1% overall 46.4% MET 50.0% BUP/NLX
Oviedo-Joekes ³⁸ , 2010, Canada	Diacetylmorphine vs hydromorphone	Treatment-refractory; 140 (not provided)	Diacetylmorphine, hydromorphone	In MAT at 12 months	No difference: 87.8% Diacetyl 88.0% Hydromor
Amass ³⁹ , 2011, 10 European countries	Direct induction (DI) vs indirect induction (II)	In MAT; 187 (80.2)	BUP/NLX	In MAT at 1 month	No difference: 81.8% DI 80.8% II
Bisaga ⁴⁰ , 2011, USA	Memantine (M) 60 mg/day vs M 30 mg/day vs P; all received therapy	New to MAT; 81 (81.5)	NTX	In MAT at 3 months	No difference: 22.0% M-60 19.0% M-30 26.0% P
Stein ⁴¹ , 2010, USA	Escitalopram (for depression) vs P; all received physician management	Depression symptoms; 147 (76.0)	BUP	In MAT at 3 months	No difference: 66.7% Escit 44.0% P
Oliveto ⁴² , 2011, USA	Disulfiram vs P; all received cognitive behavioral therapy (CBT)	Cocaine dependent; 161 (55.9)	MET	In MAT at 3.5 months	No difference: Rates not provided: 64.8% overall
Liebschutz ⁴³ , 2014, USA	Detoxification (detox) vs facilitated linkage to treatment	Medically hospitalized, not seeking addiction treatment; 145 (71.2)	BUP/NLX	In MAT at 6 months	3.0% Detox 16.7% Linkage
Chen ⁴⁴ , 2013, China	MET+contingency management (CM) vs MET only	New to MAT; 246 (92.3)	MET	In MAT at 3 months	81.7% MET+CM 67.5% MET
Hser ⁴⁵ , 2011, China	CM vs usual care (UC)	MAT patients; 319 (76.2)	MET	In MAT at 3 months	81.0% CM 67.0% UC
Dunn ⁴⁶ , 2013, USA	CM vs prescription (take-home MAT)	Unemployed, in detox or on street; 67 (61.2)	NTX	In MAT at 6 months	54.0% CM 16.0% Prescrip
Holland ⁴⁷ , 2012, Scotland	Supervision: None vs 2 times per week vs daily	In MAT for 3 months at baseline; 60 (70.0)	MET	In MAT at 3 months	No difference: 94.1% None

<u>First author, year, country</u>	<u>Conditions</u>	<u>Sample N (% Male)</u>	<u>Medication</u>	<u>Retention outcome</u>	<u>Retention rate</u>
Chawarski ⁴⁸ , 2011, China	Daily medication (DM) vs DM plus weekly drug and HIV counseling (DM plus)	Heroin-dependent; 37 (81.0)	MET	In MAT at 6 months	85.7% 2x wk 72.7% Daily
Jaffray ⁴⁹ , 2014, Scotland	Pharmacies randomized to intervention (pharmacists received motivational interviewing [MI] training & resources) vs UC	Mainly unemployed; 76 pharmacies; 542 patients (63.6)	MET	In MAT at 6 months	No difference: 83.3% DM plus 76.2% DM
Marsch ⁵⁰ , 2013, USA	MAT+counseling vs MAT+reduced counseling+ web-based education	New to MAT; 160 (75.0)	MET	In MAT at 12 months	No difference: 88% MI 81% UC
Schwartz ⁵¹ , 2011, USA	Interim (daily administration +emergency counseling; counseling; I) vs standard (take-home administration +regular counseling; S) vs restored (S+counselor reduced caseload; R); 2 sites	New to MAT; 230 (70.0)	MET	In MAT at 4 months	No difference: 91.9% I 80.8% S 88.9% R
Schwartz ⁵² , 2011, USA	I vs S vs R	On MAT program wait list; 230 (70.0)	MET	In MAT at 12 months	No difference: 60.6% I 54.8% S 37.0% R
Ling ⁵³ , 2013, USA	CBT vs CM vs CBT+CM vs no behavioral treatment	Community and treatment settings; 202 (69.3)	BUP	In behavioral treatment at 4 months	No difference: 71.7% CBT 69.4% CM 73.5% CBT +CM 64.7% None
Mitchell ⁵⁴ , 2013, USA	Outpatient (OP) counseling vs intensive outpatient (IOP) counseling	African-Americans starting MAT; 300 (62.3)	BUP	In MAT at 6 months	No difference: 58.7% OP 56.6% IOP
Ruetsch ⁵⁵ , 2012, USA	Telephone support (TS) vs vs UC (324 provider sites)	New to MAT; 1426 (59.0)	BUP	In MAT at 12 months	No difference: 55.0% TS 56.1% UC
Tetrauit ⁵⁶ , 2012, USA	Physician management (PM) vs PM +enhanced medical management (EMM)	HIV+; 47 (83.0)	BUP/NLX	In MAT at 3 months	No difference: 80.0% PM 59% PI +EMM
Jones ⁵⁷ , 2011, USA	Helping (motivational enhancement therapy, education, case and contingency management) vs control (support group)	Non-treatment seeking partners of opioid-dependent pregnant women; 62 (100)	Detox plus aftercare or MET	Days of treatment (most commonly MAT), past month, up to 30	No difference; H; M=-15.2 (SD=-2.0) C; M=14.9 (SD=-6.4)
Coviello ⁵⁸ , 2010, USA	NTX plus psychosocial treatment only; all were under judicial supervision	Offenders; 111 (82.0)	NTX	In treatment (MAT or psychosocial) at 6 months	No difference: 32.0% NTX 29.0% psychosoc

Note: Reported retention rates within studies are significantly different unless otherwise noted. BUP = buprenorphine, NTX = naltrexone, MET = methadone, NLX = naloxone; P = placebo, Med = median, inj = injectable, HAT = heroin-assisted treatment, CBT = cognitive behavioral therapy, I = interim, S = standard, R = restored, M = mean, SD = standard deviation

Summary of non-RCT published studies on treatment factors associated with retention in medication-assisted treatment for opiate dependence (N=17)

Table 2.

First author, year, country	Design	Sample N (% Male)	Medication	Retention outcome	Retention rate
Gryczynski ⁵⁹ , 2013, USA	Prospective cohort, MET vs BUP; secondary analysis of two RCTs	African-Americans entering MAT; 478 (65.2)	MET, BUP	In MAT at 6 months	78.1% MET 57.7% BUP
Pinto ⁶⁰ , 2010, England	Prospective cohort, MET vs BUP; all received care coordination	Requesting MAT; 361 (75.0)	MET, BUP	In MAT at 6 months	69.6% MET 42.5% BUP
Bouness ⁶¹ , 2013, France	Prospective cohort	Treatment settings; 151 (74.0)	MET, BUP	In MAT at 12 months	78.0% MET 26.0% BUP
Serpelloni ⁶² , 2013, Italy	Retrospective cohort (65 publicly-funded addiction treatment sites)	Patients in MAT in 2010; 8,145 (84.2)	MET, BUP	Days of stay during 2010	MET: M=246.2 (SD=110.1) BUP: M=240.5 (SD=111.7)
Hao ⁶³ , 2013, China	Prospective cohort, MET vs Jitai tablets; all received psychosocial counseling	Completed detox; 386 (84.4)	MET, Jitai tablets	In MAT at 12 months	85.0% MET 74.3% Jitai
Gryczynski ⁶⁴ , 2014, USA	Prospective cohort; secondary analysis of RCT studying counseling	African-Americans entering MAT; 297 (61.9)	BUP	In MAT at 6 months	57.9% overall; retention associated with higher BUP dose, especially early in treatment
Curcio ⁶⁵ , 2011, Italy	Quasi-experimental: MET vs BUP/NLX; 10 sites	Public outpatients; 3,812 (89.8)	MET, BUP/NLX	In MAT at 12 months	No difference; 92.5% MET 89.4% BUP/NLX
Miotto ⁶⁶ , 2012, USA	Quasi-experimental: opioid treatment program (OTP), individual counseling vs primary care (PC), brief counseling vs psychosocial program (PP) with group CBT	Community sample; 94 (58.0)	BUP/NLX	In MAT at 6 months	21.4% OTP 33.3% PC 54.5% PP
Gerra ⁶⁷ , 2011, Italy	Quasi-experimental: supervised daily (SD) vs CM vs non-contingent take-home (NT); all received psychosocial treatment; 3 sites	Heroin dependent; 300 (82.0)	MET	In MAT at 12 months	58.0% SD 74.0% CM 50.0% NT CM>SD, NT
Haddad ⁶⁸ , 2012, USA	Retrospective cohort; 2 health care sites	Patients in MAT in 2007–08; 266 (69.2)	BUP	In MAT at 12 months	61.6% overall; retention associated with during-MAT receipt of psychiatric medication and substance abuse counseling
Moore ⁶⁹ , 2012, USA	Quasi-experimental: PM+weekly dispensing vs PM+3 times per week dispensing+CBT	Primary care patients; 58 (74.1)	BUP/NLX	In MAT at 3 months	Marginal difference: 68.0% PM+CBT 87.0% PM
Winklbauer-Hausknecht ⁷⁰ , 2012, Austria	Quasi-experimental: vouchers for attendance vs vouchers for attendance +drug free biological samples	Pregnant women in multidisciplinary care; 59 (0.0)	MET, BUP	In MAT at 1 month post-delivery	No difference: 22% attendance 10% attendance + samples
Coviello ⁸² , 2012, USA	Prospective cohort; 5 sites	Offenders; 61 (92.0)	Extended release injectable NTX	In MAT at 6 months	40.0%
Fox ⁹³ , 2012, USA	Prospective cohort	HIV+82 (72.0)	BUP	In MAT at 6 months	56.0%

<u>First author, year, country</u>	<u>Design</u>	<u>Sample N (% Male)</u>	<u>Medication</u>	<u>Retention outcome</u>	<u>Retention rate</u>
Fiellin ⁹⁴ , 2011, USA	Prospective cohort	HIV+303 (67.7)	BUP/NLX	In MAT at 12 months	49.0%
Apelt ⁹⁵ , 2013, Germany	Prospective cohort	Patients who had received MAT then began BUP-NLX; 337 (76.6)	BUP/NLX	In MAT at 12 months	57.1% overall
Blanken ⁷³ , 2010, Netherlands	Prospective cohort; all received psychosocial, medical support	Positive responders to HAT; 149 (83.2)	MET plus heroin	In MAT at 4 years	55.7%

Note: Reported retention rates within studies are significantly different unless otherwise noted. BUP = buprenorphine, MET = methadone, NLX = naloxone,

NTX = naltrexone, HAT = heroin-assisted treatment